Temozolomide resistance in glioblastoma; effect of calcium-binding protein S100P

Glioblastoma multiforme (WHO grade IV) is a devastating and aggressive primary brain tumor, characterized by poor prognosis and lack of efficient standard-of-care treatments. The vast majority of patients receiving radiotherapy along with Temozolomide chemotherapy, tend to develop Temozolomide resistance, hence resulting in tumor recurrence. Regardless of the advanced Glioblastoma treatments, Temozolomide remains the backbone of high-grade glioblastoma treatment. The poor prognosis and chemoresistance of glioblastoma raise the necessity to further-develop and investigate in order to identify novel molecular targets involved with chemoresistance in glioblastoma. The Calcium-Binding Protein S100P is involved with Chemoresistance, metastasis, as well as poor clinical outcomes in many malignancies. This research aims to shed light on the role played by Calcium-Binding Protein (S100P) in Temozolomide resistance in glioblastoma. Keywords: Brain Cancer, Glioblastoma, Temozolomide, Chemoresistance, Calcium-Binding Protein S100P.